GO
Loading...

GlaxoSmithKline PLC

More

  • WHO: Millions of Ebola vaccine doses ready in 2015 Friday, 24 Oct 2014 | 8:50 AM ET

    Still, the agency warned it's not clear whether any of these will work against the deadly virus that has already killed at least 4,877 people this year in West Africa. Trials of those two most advanced vaccines— one developed by GlaxoSmithKline in cooperation with the U.S. National Institutes of Health, the other developed by the Canadian Public Health Agency...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies for the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate production and clinical testing of three...

  • Wall Street fell as Boeing Co and Biogen Idec tumbled after their results disappointed investors, the two biggest drags on the S&P 500.. The retreat on Wall Street pulled MSCI's gauge of global equity performance lower, but European stocks closed higher, largely driven by earnings. GlaxoSmithKline rose 2.6 percent in London after saying it expects an Ebola...

  • Oct 22- A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter. Advent and Avista have prevailed in an auction for Kremers Urban, which attracted interest from other private equity firms...

  • *European Commission to provide 100 million euros. The move shows how momentum is building to get medical interventions-- and particularly vaccines-- to West Africa as soon as possible to control the world's worst Ebola outbreak, which, according to official figures, has killed nearly 5,000 people, most of them in Liberia, Sierra Leone and Guinea.

  • *Exploring IPO of minority stake in ViiV Healthcare. LONDON, Oct 22- GlaxoSmithKline, battered by weak U.S. drug sales and a bribery scandal in China, is looking to float its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting. As a standalone company ViiV Healthcare would be among the top 40 companies in London's...

  • Both Yahoo Inc and Broadcom beat revenue expectations late Tuesday, putting the benchmark S&P 500 on track for its biggest five-day rally since December 2011. Yahoo rose 5.9 percent, Broadcom jumped 6.8 percent and GlaxoSmithKline rose 3.6 percent in London after saying it expects a vaccine against Ebola to be ready later this year. Both Yahoo and Broadcom...

  • *Exploring IPO of minority stake in ViiV Healthcare. LONDON, Oct 22- GlaxoSmithKline, battered by weak U.S. drug sales and a bribery scandal in China, set out a bold recovery plan on Wednesday, including an initial public offering of part of its fast-growing HIV and AIDS drugs business. As a standalone company ViiV Healthcare would be among the top 40 companies in...

  • BUSINESS-NEWS-SCHEDULE AT 1230 GMT / 8.30 AM ET Wednesday, 22 Oct 2014 | 9:05 AM ET

    LONDON- European shares slip and the euro hit a one-week low as reports that at least 11 banks could fail a region-wide financial health check this weekend offset hopes of corporate bond buying by the ECB. MADRID/ VIENNA- The European Central Bank cautions against speculation over the outcome of its stress tests after a media report says at least 11 banks have...

  • GSK sees first Ebola vaccine doses ready late this year Wednesday, 22 Oct 2014 | 8:08 AM ET

    LONDON, Oct 22- GlaxoSmithKline expects to have the first doses of its Ebola vaccine ready late this year and is looking to work with the rest of the pharmaceutical industry to scale up production. "I fully anticipate that the initial supply should be available before the year end," Chief Executive Andrew Witty told reporters on Wednesday after reporting...

  • Johnson & Johnson plans Ebola vaccine testing Wednesday, 22 Oct 2014 | 7:42 AM ET

    NEW BRUNSWICK, N.J.— Johnson& Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. Johnson& Johnson also plans to test whether its vaccine protects against the version causing the outbreak, which has killed more than 4,500 people. Johnson& Johnson is developing the vaccine...

  • *J&J says has discussed collaboration with GlaxoSmithKline. Johnson& Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine. The World Health Organization hopes that tens of thousands of people in...

  • GlaxoSmithKline holds dividend, eyes IPO of HIV unit Wednesday, 22 Oct 2014 | 7:23 AM ET

    LONDON, Oct 22- GlaxoSmithKline kept its dividend unchanged for the third quarter, breaking a run of steadily rising payouts, as U.S. pricing pressure on its top-selling lung drug Advair eroded sales and profit. It also announced a further cost-cutting programme and said it would explore an IPO of a minority stake in its HIV business ViiV Healthcare.

  • Earnings set to drive markets again Wednesday, 22 Oct 2014 | 5:55 AM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • LONDON, Oct 22- Johnson& Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May. There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two- from...

  • Earnings set to take markets' center stage Tuesday, 21 Oct 2014 | 7:29 PM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • Ebola vaccine could be ready in 3 months: CEO Tuesday, 21 Oct 2014 | 6:45 PM ET
    A CDC safety training course on Ebola in Anniston, Ala.

    A new Ebola vaccine could be ready to send to West Africa soon, NewLink Genetics' Charles Link says.

  • WHO: Ebola vaccine trials in W. Africa in January Tuesday, 21 Oct 2014 | 7:19 AM ET

    GENEVA— Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday. The Ebola outbreak in West Africa has already killed over 4,500 people, mostly in Liberia, Guinea and Sierra Leone, since it emerged 10...

  • Ship bound TX hospital worker negative for Ebola Sunday, 19 Oct 2014 | 9:56 AM ET
    In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.

    A Dallas hospital lab worker in isolation on a cruse after possible exposure to Ebola has tested negative for the disease.